Soleno Therapeutics, Inc.SLNONASDAQ
Loading
EPS Growth Under PressureDecelerating
Percentile Rank92
3Y CAGR+107.3%
5Y CAGR+8.6%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
+107.3%/yr
vs -51.0%/yr prior
5Y CAGR
+8.6%/yr
Recent acceleration
Acceleration
+158.3pp
Accelerating
Percentile
P92
Near historical high
vs 5Y Ago
1.5x
Solid growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 95.92% |
| Q3 2025 | 625.19% |
| Q2 2025 | 90.18% |
| Q1 2025 | 25.20% |
| Q4 2024 | 30.60% |
| Q3 2024 | -221.05% |
| Q2 2024 | 3.39% |
| Q1 2024 | -37.21% |
| Q4 2023 | 54.74% |
| Q3 2023 | -17.28% |
| Q2 2023 | 7.95% |
| Q1 2023 | -51.72% |
| Q4 2022 | 10.77% |
| Q3 2022 | 9.72% |
| Q2 2022 | 32.71% |
| Q1 2022 | -101.89% |
| Q4 2021 | 65.36% |
| Q3 2021 | 27.14% |
| Q2 2021 | -27.27% |
| Q1 2021 | -175.00% |
| Q4 2020 | 63.64% |
| Q3 2020 | 31.25% |
| Q2 2020 | -23.08% |
| Q1 2020 | 63.89% |
| Q4 2019 | -1300.00% |
| Q3 2019 | 109.53% |
| Q2 2019 | -42.17% |
| Q1 2019 | -2313.33% |
| Q4 2018 | 107.85% |
| Q3 2018 | 66.07% |
| Q2 2018 | -95.49% |
| Q1 2018 | 25.39% |
| Q4 2017 | 34.24% |
| Q3 2017 | 6.08% |
| Q2 2017 | 26.56% |
| Q1 2017 | -16.58% |
| Q4 2016 | 44.23% |
| Q3 2016 | 22.86% |
| Q2 2016 | -5.01% |
| Q1 2016 | -12.07% |